| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3120ae9cab5bb4831f0cc16288966367 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8117 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-865
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-57
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-81
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-81 |
| filingDate |
1991-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5eb47f9ce8263729920571ad616822b8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eb4a1218d224cd6d8a425ed5cdd5ad37
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0dde301c7619b6dcef071cab6aac6ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10b43db19199938e7e28877c4fc56ba2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b49d7b1acf788fd62ae64525abf920ea
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6a1a3c6c57ebe1df00b115fa8281620 |
| publicationDate |
2001-04-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
SK-281540-B6 |
| titleOfInvention |
APROTININE ANALOGUE, METHOD OF PRODUCTION, PHARMACEUTICAL COMPOSITION AND THEIR USE |
| abstract |
The described aprotinin analogs with reduced nephrotoxicity have at least one positively charged amino acid residue located outside the protease binding site removed or replaced with a neutral or negatively charged amino acid residue and / or where at least one negatively charged amino acid residue is inserted or added to achieve a reduced positive charge. or wherein at least one neutral amino acid residue is replaced with a negatively charged amino acid residue and / or wherein one or more non-protease binding site amino acid residues are removed, added or replaced by one or more amino acid residues to achieve reduced analog stability temperature in aqueous solution at pH 10-10. residues. Further described is a DNA sequence encoding aprotinin analogs, a recombinant vector, a cell comprising said vector, and a method of producing aprotinin analogs by culturing said cell. |
| priorityDate |
1990-10-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |